KRAS and cancer: While not definitively establishing the absence of a double-positive cell population, we confirmed reduced levels of inhibition as shown by higher levels of phosphorylated ERK in selpercatinib-treated cells co-expressing the observed KRAS alleles, (Supplemental Fig. 8), indicating the existence of distinct cancer cell populations from the sensitizing RET alteration.